Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers.
Cuadros M, Cano C, Garcia-Rodriguez S, Martín JL, Poyatos-Andujar A, Ruiz-Cabello F, Pedrinaci S, Durán G, Benavides M, Bautista-Ojeda MD, Pereda T, Benitez-Cantos MS, Medina P, Blanco A, Gonzalez A, Lizardi P. Cuadros M, et al. Among authors: duran g. BMC Med Genomics. 2022 Mar 4;15(1):45. doi: 10.1186/s12920-022-01183-2. BMC Med Genomics. 2022. PMID: 35246124 Free PMC article.
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M, Alcaide-Garcia J, Torres E, Gil-Calle S, Sevilla I, Wolman R, Durán G, Álvarez M, Reyna-Fortes C, Ales I, Pereda T, Robles M, Kushnir M, Odegaard J, Faull I, Alba E. Benavides M, et al. Among authors: duran g. ESMO Open. 2022 Jun;7(3):100481. doi: 10.1016/j.esmoop.2022.100481. Epub 2022 May 4. ESMO Open. 2022. PMID: 35525184 Free PMC article.
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P, Benavides M, Falcó E, Muñoz A, Gómez A, Sastre J, Rivera F, Montagut C, Salgado M, López-Ladrón A, López R, Ruiz de Mena I, Durán G, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Among authors: duran g. Oncologist. 2018 Nov;23(11):1271-e128. doi: 10.1634/theoncologist.2018-0316. Epub 2018 Aug 17. Oncologist. 2018. PMID: 30120161 Free PMC article.
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M, Gutiérrez V, Alcaide J, Alés I, Villar E, Gil S, Durán G, Martínez J, Carabantes F, Bretón JJ, Benavides M. Cobo M, et al. Among authors: duran g. Lung Cancer. 2007 May;56(2):255-62. doi: 10.1016/j.lungcan.2006.12.013. Epub 2007 Feb 5. Lung Cancer. 2007. PMID: 17276537 Clinical Trial.
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.
García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Among authors: duran g. Drugs Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. Epub 2021 Feb 22. Drugs Aging. 2021. PMID: 33615402 Free PMC article.
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Sepúlveda-Sánchez JM, Gil-Gil M, Alonso-García M, Vaz Salgado MÁ, Vicente E, Mesía Barroso C, Rodríguez Sánchez Á, Durán G, De Las Peñas R, Muñoz-Langa J, Velasco G, Hernández-Laín A, Hilario A, Navarro Martín M, Benavides M, Oleaga L, Cantero Montenegro D, Ruano Y, Sánchez-Gómez P, Martín-Soberón MC, Morales-Llombart R, Pachón V, Pineda E. Sepúlveda-Sánchez JM, et al. Among authors: duran g. Target Oncol. 2020 Oct;15(5):613-622. doi: 10.1007/s11523-020-00754-6. Target Oncol. 2020. PMID: 33025213 Clinical Trial.
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J, Fernández-Rodríguez MC, Casadevall D, García-Alfonso P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Vidal J, et al. Among authors: duran g. Clin Cancer Res. 2023 Jan 17;29(2):379-388. doi: 10.1158/1078-0432.CCR-22-1696. Clin Cancer Res. 2023. PMID: 36074154
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C, Azuara D, Viéitez JM, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar R. Santos C, et al. Among authors: duran g. Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082. Ann Oncol. 2019. PMID: 30840064 Free article. Clinical Trial.
Metabolic changes induced by galactose.
Jover SE, Duran GS, Manso MJ, Velasco AR, Paradinas JC. Jover SE, et al. Among authors: duran gs. Experientia. 1975 Feb 15;31(2):153-4. doi: 10.1007/BF01990676. Experientia. 1975. PMID: 1112340 No abstract available.
233 results